GHRS

GH Research PLC: 2025 Annual Report (Form 20-F) Summary

Business Context and Reporting Period

Company: GH Research PLC (Ireland)
Reporting Period: Fiscal year ended December 31, 2025
Business Model: Clinical-stage biopharmaceutical company developing proprietary mebufotenin therapies for psychiatric and neurological disorders, primarily Treatment-Resistant Depression (TRD).
Key Products: GH001 (inhalable mebufotenin) and GH002 (intravenous mebufotenin).
Accounting Basis: International Financial Reporting Standards (IFRS).
Capital Structure: 62,029,395 ordinary shares outstanding as of December 31, 2025.

Key Financial Metrics (Year Ended Dec 31, 2025)

Material Changes vs. Prior Period

• Capital Raise: In February 2025, the Company completed a public offering of 10,000,000 ordinary shares at $15.00 per share, generating net proceeds of $139.8 million. This significantly increased cash reserves from $182.6 million to $280.7 million.
• Expense Growth: Net loss increased by $9.3 million (24%) year-over-year. General and Administrative (G&A) expenses rose by $6.7 million, driven by professional fees and increased share-based compensation ($4.6 million in 2025 vs. $0.7 million in 2024). R&D expenses increased by $3.7 million, primarily due to technical development and employee costs.
• Regulatory Milestone: The FDA lifted a clinical hold on the Investigational New Drug (IND) application for GH001 in December 2025, following the submission of additional toxicology studies and device verification data.
• Share-Based Compensation: Total share-based compensation expense surged to $8.5 million in 2025 compared to $1.2 million in 2024, reflecting new option grants to management and employees.

Guidance, Outlook, and Risks

Outlook: Management expects to continue incurring significant losses for the foreseeable future as it advances clinical trials for GH001 and GH002. The Company believes its current cash position is sufficient to fund operations for at least the next 12 months. No revenue is expected from product sales for several years.

Key Risks:

• Regulatory & Controlled Substances: Mebufotenin is a Schedule I controlled substance in the U.S. Commercialization requires rescheduling by the DEA, which is uncertain. The FDA previously placed GH001 on clinical hold (lifted Dec 2025) due to respiratory tract findings in toxicology studies.
• Device Development: GH001 requires a proprietary aerosol delivery device. Development is ongoing, and reliance on third-party devices or failure to validate the proprietary device could delay trials.
• Capital Needs: The Company has no committed source of additional capital. Failure to raise funds could force delays or termination of development programs.
• PFC Status: The Company believes it was a Passive Foreign Investment Company (PFIC) for 2025 and anticipates this status for 2026, which may have adverse tax consequences for U.S. investors.
• Internal Controls: The Company previously identified material weaknesses in internal controls over financial reporting, which have been remediated as of December 31, 2025.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $280.7 million cash balance against the projected burn rate for the upcoming pivotal trials in the U.S.
• Device Validation: Confirm the status of the proprietary aerosol delivery device for GH001 and the timeline for its use in pivotal trials.
• Rescheduling Pathway: Monitor the DEA's rescheduling process for mebufotenin, a critical prerequisite for U.S. commercialization.
• Share-Based Compensation: Assess the impact of the significant increase in share-based compensation ($8.5M) on future dilution and expense management.
• PFIC Status: Consult tax advisors regarding the implications of the Company's PFIC status for U.S. shareholders.